View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 2, 2011

Calypso receives IDE approval for lung cancer study

The US Food and Drug Administration (FDA) granted Investigational Device Exemption (IDE) approval for Calypso Medical's clinical study evaluating Calypso systems' viability to precisely track lung cancer tumours during radiation therapy.

The US Food and Drug Administration (FDA) granted Investigational Device Exemption (IDE) approval for Calypso Medical’s clinical study evaluating Calypso systems’ viability to precisely track lung cancer tumours during radiation therapy.

Utilising miniaturised, non-ionising implanted devices called beacon electromagnetic transponders, the Calypso system continuously and accurately tracks the location of cancerous tumours.

Patient enrollment in the study is planned at Washington University in St. Louis and the Cancer Treatment Centers of America in Tulsa, Oklahoma, US.

University Hospital Basel, Switzerland, Department of Radiation Oncology head Frank Zimmermann said the anchored beacon transponders used by the Calypso System provide them with immediate and precise information regarding the location and movement of tumours, which may help make radiation a feasible curative option for a broader group of patients suffering from lung cancer.

Southwestern Regional Medical Center Cancer Treatment Centers of America interventional pulmonologist Daniel Nader said the clinical study is to assess the clinical experience and safety of anchored transponders in the small airways of patients with lung cancer.

The US Food and Drug Administration previously cleared beacon transponders, for permanent implantation in the prostate and prostatic bed to provide precise, continuous information on the tumour location during radiation therapy.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management